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ABSTRACT 
Mitochondria are highly dynamic organelles, undergoing continuous fission and fusion. 
The DNM1L gene encodes for the DRP1 protein, an evolutionary conserved member of 
the dynamin family, responsible for fission of mitochondria, and having a role in the 
division of peroxisomes, as well. DRP1 impairment is implicated in several neurological 
disorders and associated with either de novo dominant or compound heterozygous 
mutations. In five patients presenting with severe epileptic encephalopathy we identified 
5 de novo dominant DNM1L variants, the pathogenicity of which was validated in a yeast 
model. Fluorescence microscopy revealed abnormally elongated mitochondria and 
aberrant peroxisomes in mutant fibroblasts, indicating impaired fission of these 
organelles. Moreover, a very peculiar finding in our cohort of patients was the presence, 
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in muscle biopsy, of core like areas with oxidative enzyme alterations, suggesting an 
abnormal distribution of mitochondria in the muscle tissue. 
Graphical Abstract 
DNM1L de novo dominant variants impaired mitochondrial fission and produced 
abnormal distribution of mitochondria in the muscle tissue. 
 
KEY WORDS: DNM1L; mitochondrial dynamics; mitochondrial fission; mitochondrial 
disorders; epileptic encephalopathy; muscle biopsy. 
INTRODUCTION 
The DNM1L (dynamin 1 like) gene encodes for the DRP1 protein, an evolutionary 
conserved member of the dynamin family, responsible for fission of mitochondria, a 
process required for normal mitochondrial dynamics and distribution. When activated, 
DRP1 translocates from a cytosolic pool to the outer mitochondrial membrane, where it 
oligomerizes, hydrolyzes GTP, and assembles into spiral filaments around mitochondrial 
tubules, allowing the organelles division. After the completion of this process, DRP1 
spirals likely disassemble from mitochondria for future rounds of mitochondrial fission 
(Youle et al., 2012). 
DRP1 has an important role in the maintenance of mitochondrial (Otsuga et al., 1998) 
and peroxisomal morphology (Pitts, 2004, Schrader et al., 2016), mediating organelle 
membrane remodeling during a variety of cellular processes. Mitochondria exist as a 
dynamic tubular network with projections that move, break, and reseal in response to 
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local environmental changes; the size and morphologic arrangement of mitochondria are 
due to a dynamic balance between mitofusins-dependent mitochondrial fusion and 
DRP1-dependent mitochondrial fission (Santel & Fuller, 2001). 
Defects in mitochondrial dynamics, including the inhibition of mitochondrial fission and 
fusion, are responsible for many human diseases (Lenaers et al., 2012; Stuppia et al., 
2015; Kim et al., 2017; Pozo Devoto & Falzone, 2017; Alexiou et al., 2017). Besides 
mutations in DNM1L (Waterham et al., 2007), dysfunctions in mitochondrial fission has 
been also associated with mutations in genes codifying for adaptors of DRP1, such as 
MFF and MID49/MIEF2 (Shamseldin et al., 2012; Koch et al., 2016; Bartsakoulia et al., 
2018). 
DRP1 impairment is implicated in several neurological disorders associated with either 
de novo dominant or compound heterozygous DNM1L mutations (MIM #603850). 
Encephalopathy due to defective mitochondrial and peroxisomal fission-1 is 
characterized by early onset with psychomotor delay and hypotonia, progressive course 
and death in childhood. Many patients develop refractory seizures, consistent with an 
epileptic encephalopathy, and thereafter show neurological decline. Age at onset, 
symptoms, and severity are variable, and some patients may not have 
clinical/biochemical evidence of mitochondrial or peroxisomal dysfunction (Fahrner et 
al., 2016; Nasca et al., 2016). 
Better known clinical conditions that occur more frequently are related to defects in 
factors that conversely are implicated in mitochondrial membrane fusion such as 
Charcot–Marie–Tooth disease type 2A caused by dominant or recessive mutations in 
MFN2 (mitofusin 2, MIM #608507), and optic atrophy or Leigh-like infantile 
encephalopathies caused by dominant or recessive mutations in OPA1 (MIM #605290). 
Additional rare neurological phenotypes of “optic atrophy plus” syndrome and 3-
methylglutaconic aciduria or cataracts are related to recessive or dominant mutations in 
OPA3 (MIM #606580), a factor involved in mitochondrial shaping; a mild Charcot–
Marie–Tooth disease type 2K is caused by biallelic recessive mutations in GDAP1 (MIM 
#606598), that encodes for a mitochondrial protein involved in mitochondrial dynamics; 
and finally mitochondrial myopathy and ataxia has been recently reported to be due to 
dominant or recessive mutations in MSTO1 (MIM #617619), encoding a cytoplasmic 
pro-mitochondrial fusion protein (Nasca et al., 2017). 
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Cultured fibroblasts from patients with these genetic conditions usually show either 
mitochondrial fragmentation, corresponding to genetic defects of factors implicated in 
mitochondrial membrane fusion (MFN2, OPA1) (Zanna et al., 2008), or abnormally 
elongated mitochondria and aberrant peroxisomes in cases with mutations in MFF (Koch 
et al., 2016) and DNM1L (Nasca et al., 2016).  
Histochemical and ultrastructure characterization of skeletal muscle biopsies of subjects 
harboring OPA1 mutations showed the presence of cytochrome c oxidase-deficient fibers 
associated with multiple mitochondrial DNA deletions in the majority of patients, either 
affected by dominant optic atrophy plus variants or with isolated optic nerve involvement 
(Yu-Wai-Man et al., 2010). On the other hand, few papers have reported studies on 
muscle biopsy of patients with mutations in additional genes regulating mitochondrial 
morphology, and no abnormalities have been found (Waterham et al., 2007; Fahrner et 
al., 2016; Yoon et al., 2016; Koch et al., 2016; Nasca et al., 2016), although Chao et al 
(2016) reported mitochondrial shape abnormalities at electron microscopy. 
Here we describe on a series of 5 sporadic patients affected by severe epileptic 
encephalopathy associated with heterozygous mutations in DMN1L showing peculiar 
mitochondrial distribution changes in the muscle biopsy. So far, these abnormalities of 
mitochondrial distribution in muscle seem to be specific for the DMN1L related epileptic 
encephalopathy. 
METHODS 
Standard protocol approvals, registrations and patients consents 
The study was approved by the Ethical Committees of the Bambino Gesù Children’s 
Hospital, Rome, Italy, and the C. Besta Neurological Institute, Milan, Italy, in agreement 
with the Declaration of Helsinki. 
Histological, ultrastructural and biochemical analyses in muscle 
Cryostatic cross-sections of quadriceps muscle biopsies were processed according to 
standard histochemical and immunohistochemical procedures. Immunohistochemical 
studies were performed with rabbit polyclonal TOMM20 antibody (Santa Cruz 
Biotechnology) (in green) and with monoclonal antibody against merosin (Chemicon) (in 
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red). Confocal microscopy was performed on a Leica TCS-SP8X laser-scanning confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with white light laser 
(WLL) source, 405nm diode laser, 3 Internal Spectral Detector Channels (PMT) and 2 
Internal Spectral Detector Channels GaAsP. Sequential confocal images were acquired 
using a 63x-oil immersion objective (1.42 numerical aperture, Leica Microsystems) with 
a 1024x1024 format, and scan speed 400Hz. Z-reconstructions (30 stacks) were obtained 
with a z-step size of 0.3 µm. To improve contrast and resolution of mitochondrial 
distribution, confocal raw images were deconvolved by Hyvolution2 software (Leica 
Microsystems) before 3D reconstruction. Then deconvolved z-stacks were imported into 
LAS X 3D Analysis (Leica Microsystems) software to obtain their three-dimensional 
surface rendering. Each group of image was processed and analyzed using the same 
settings (i.e. laser power and detector amplification). For ultrastructural studies, muscle 
specimens were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) at 4°C. 
Samples were post-fixed with 2% OsO4 in 0.1 M cacodylate buffer (pH 7.4) for 1 h. 
Specimens were dehydrated in a graded series of ethanol and embedded in epon resin. 
Thin sections were evaluated with a transmission electron microscope (EM 109 Zeiss) 
(Fattori et al., 2018). 
Respiratory chain complexes (RCCs) activities were assayed in muscle homogenate and 
normalized to citrate synthase activity, using a previously reported spectrophotometric 
method (Bugiani et al., 2004). 
Mutational analysis 
Genomic DNA was isolated from blood and cultured skin fibroblasts using QIAamp 
DNA mini kit (QIAGEN, Valencia, CA, USA). DNA from Pt.1, Pt.2 and Pt.3 underwent 
high-throughput sequencing by TruSight One panel (Illumina, San Diego, CA) 
comprehensive of > 4.800 clinically relevant genes. The enrichment was achieved 
following manufacture instruction and the sequencing analysis was performed on MiSeq 
System. Variant-Studio software was applied for analysis, classification, and reporting of 
genomic variants. After excluding previously annotated single nucleotide changes 
occurring with high frequency in populations (>1%), we prioritized variants predicted to 
have functional impact (i.e. nonsynonymous variants and changes affecting splice sites). 
Pt.4 and Pt.5 were analyzed using a custom gene panel for the screening of 224 genes 
associated with mitochondrial diseases (Ardissone et al., 2018). Sanger sequencing was 
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used to validate all the annotated functionally relevant variants, as well as to check 
variant segregation in the families. Bioinformatics tools based on heuristic methods, 
SIFT (http://sift.jcvi.org), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) and 
Mutation Taster (http://www.mutationtaster.org/) were used for pathogenicity prediction 
of the variants. 
For the identification of multiple deletions, we performed Long Range PCR using 
TaKara LA Taq DNA Polymerase (Takara Biotechnology-Dalian Co., Ltd.) amplifying a 
11242bp mtDNA fragment with forward-4800 (5’ttcacttctgagtcccaga-3’) and backward-
16042 primers (5’ctgcttccccatgaaagagaacagagaa-3’). 
Western blotting analysis and antibodies 
For SDS-PAGE, 40 μg of fibroblasts homogenate were loaded in a 12% denaturating gel. 
Western blot (WB) was achieved by transferring proteins onto polyvinylidene difluoride 
(PVDF) membrane and probed with specific antibodies. Specific bands were detected 
using Lite Ablot Extend Long Lasting Chemiluminescent Substrate (Euroclone, Pero 
(Mi), Italy). Densitometry analysis was performed using Quantity One software (BioRad, 
Hercules, CA, USA). 
RCC subunits were detected using the following monoclonal antibodies purchased from 
MitoScience (Eugene, OR, USA): Complex I – NDUFA9; complex II – SDHB; complex 
IV – COXII; Complex V – ATP5B; porin (VDAC). Polyclonal rabbit GAPDH (Sigma-
Aldrich) and monoclonal antibody OPA1 (BD Biosciences) and DRP1 (Abcam) were 
also used. 
Biochemical analysis, Immunostaining and Imaging in fibroblasts 
Human fibroblasts were obtained from a diagnostic skin biopsy and grown in DMEM 
medium supplemented with 10% fetal bovine serum, 4.5 g/L glucose, and 50 μg/mL 
uridine. Complex V activity (in the direction of ATP synthesis) was measured in 
fibroblast mitochondria, using reported spectrophotometric methods (Rizza et al., 2009). 
Mitochondrial respiration was measured using a SeaHorse FX-96 apparatus (Agilent 
Technologies, Santa Clara, CA), as previously described (Invernizzi et al., 2012). 
To display the mitochondrial network arrangement, fibroblasts from Pt.1, Pt.2, Pt.3 were 
fixed and permeabilized using methanol:acetone (2:1) for 10 min at room temperature, 
then a blocking solution containing 5% BSA in PBS was used. The polyclonal rabbit 
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TOMM20 antibody (Santa Cruz Biotechnology) was applied overnight and visualized 
using Alexa Fluor 647 secondary antibody (Jackson ImmunoResearch), both antibodies 
were used at the dilution of 1:500. Images were acquired with a fluorescence-inverted 
microscope (Leica DMi8). An average of 8 image planes was obtained along the z-axis at 
0.2 µm increments using LASX 3.0.4 (Leica) software. For Pt.4 and Pt.5 the 
mitochondrial network was visualized in living cells using the mitochondrial fluorescent 
dye MitoTracker Red-CMXRos (Invitrogen) at final concentrations of 50 nM for 30 min; 
then images were acquired with a confocal microscope (Leica TSC-SP8). 
For peroxisomal immunostaining we used the polyclonal rabbit PMP70 antibody (Sigma-
Aldrich) applied overnight at the concentation of 1:200, followed by Alexa Fluor 488 
secondary antibody (1:500). The peroxisomal staining was visualized using the same 
parameters used above. Analysis of peroxisomal morphology was conducted using the 
image processing package ImageJ (Fiji). Images were then binarized, thresholded, and 
subjected to particle analysis to acquire form factor (“circularity”: 4π*area/perimeter2). 
Functional studies in yeast  
Yeast strains and media. The yeast strains used in this work were the haploid strain 
W303-1B (MATa leu2-3, trp1-1, can1-100, ura3-1, ade 2-1, his3-11) and its isogenic 
strain dnm1::KanR, and the hemizygous diploid strain W303 dnm1∆ (MATa/MATa leu2-
3/leu2-3, trp1-1/trp1-1, can1-100/can1-100, ura3-1/ura3-1, ade 2-1/ade2-1, his3-
11/his3-11 DNM1/dnm1::KanR). All experiments were performed in Synthetic complete 
medium (SC, 6.9 g/l yeast nitrogen base without amino acids (ForMedium), 1 g/l drop-
out mix without amino acids or bases necessary to keep plasmids) (Kaiser et al., 1994). 
Media were supplemented with carbon sources (Carlo Erba Reagents) as indicated in the 
text in liquid phase or after solidification with 20g/L agar (ForMedium). 
Construction of dnm1 mutant strains. dnm1 mutant alleles and dnm1 mutant strains were 
constructed as previously reported (Nasca et al., 2016). Briefly, dnm1 mutant alleles were 
constructed using mutagenic overlap PCR with the oligonucleotides reported in 
Supplementary Table S1, digested with BamHI and XbaI or XbaI and SalI, and subcloned 
in pFL38DNM1. In order to obtain haploid wild type or mutant strains all plasmids were 
introduced by transformation in the W303-1B dnm1Δ haploid strain and in the W303 
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dnm1Δ hemizygous diploid strain using the “LiAc/SS carrier DNA/PEG quick method” 
as previously reported (Gietz & Woods, 2002). 
Yeast analyses. Spot assay was performed by spotting 5x104, 5x103, 5x102 and 5x101 
cells on SC supplemented with different carbon sources. Petite frequency was measured 
as previously reported (Baruffini et al., 2010) in six to eight independent clones for each 
strain. Oxygen consumption rate was measured in SC medium as previously described 
(Goffrini et al., 2009) on five independent clones, after growth in conditions, which 
minimized the petite frequency, which was lower than 5%. (Nolli et al., 2015). All 
experiments were performed at 37°C, except for the measurement of the petite frequency 
in the diploid strains, which was performed at 28°C. 
Statistical analysis 
For each experiment, data obtained were calculated as the mean of replicates ± standard 
deviation (SD). For analysis on peroxisomal morphology data were analysed using 
unpaired two-tailed Student's t-tests; for yeast experiments, data were compared with 
one-way ANOVA followed by Bonferroni’s test. 
Structural analysis 
The residues affected by the missense mutations described in this work (p.Gly223Val, 
p.Gly362Asp, p.Phe370Cys, and p.Arg403Cys) were mapped on crystal structures of 
homologues proteins. The crystal structure of a dimeric human dynamin-1-like protein 
(Protein Data Bank, PDB, 3W6O) was used for the p.Gly223Val mutation. The crystal 
structure of the Dynamin-3 tetramer (PDB 5A3F) was used for the p.Gly362Asp, 
p.Phe370Cys, and p.Arg403Cys mutations. The cryo-electron microscopy structure of 
human dynamin-1 co-assembled with MID49 (PDB 5WP9) was used to obtain the 
detailed view of the site of the p.Phe370Cys mutation. Molecular structures were 
rendered with PyMOL (http://www.pymol.org). 
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RESULTS 
Clinical features and Brain MRI findings 
Patient 1 is a girl single-born from unrelated healthy young parents. At birth, there was 
no breathing distress, no jaundice, and weight was 2.850 kg. She had normal motor 
milestones in the first year of life and was able to walk without any support at age 17 
months. She pronounced her first words around 1 year of age, and later at age 4 years she 
started in kindergarten and had good attendance and integration. At age 2 years and a 
half, the child manifested generalized clonic seizures while falling asleep, and then 
displayed an ataxic syndrome with prominent intentional and postural tremor that 
persisted for 2 weeks. About 7-8 weeks later, a cluster of myoclonic seizures of face and 
left side limbs with vomiting and drooling appeared together with relapsing of ataxia. 
She was admitted at a local hospital were a brain MRI showed T2 hyperintensities in the 
posterior white matter regions and some T2 hyperintensities in the cortical areas. More 
recently, a MRI performed at age 6 years showed moderate global cerebral and cerebellar 
atrophy (Figure 1A-B and E-F). Serial MRIs taken in the same month at different days 
showed that the cortical DTW restriction hyperintensity in the right precentral gyrus and 
in the pallidum and thalamus of the right hemisphere (Figure 1C) spontaneously vanished 
20 days later when a serial brain MRI was performed (Figure 1D). She was admitted at 
our hospital for a Super refractory Status Epilepticus (SRSE) which began one month 
before, and was unresponsive to multiple doses of tiopentone. SRSE was treated with 
propofol and with high dose of topiramate and perampanel, and was characterized by 
repetitive to continuous focal myoclonic seizures clinically lateralized to the right side, 
especially involving the face and the right arm. The polymyographic video/EEG 
recordings showed high amplitude theta-delta activity, lateralized to the left side. Ictal 
EEG confirmed the cortical nature of the seizures as it was characterized by low 
amplitude rhythmic fast discharge lateralized to the left side evolving into a focal spike-
and-wave complexes, corresponding to the clinical focal contralateral myoclonus. 
Intercritical EEG confirmed the interhemispheric asymmetry with persistent slow activity 
over the left central regions. SRSE lasted for 50 days and was the only status epilepticus 
she had so far. 
Patient 2 is a boy born as a preterm infant from TC scheduled at 36 weeks of gestational 
age because prenatal ultrasound monitoring indicated a fetal growth restriction appearing 
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in the last trimester. At birth weight was 2.020 kg, Apgar 9-10. The neonatal period was 
uneventful, and developmental milestones were regular because he started to walk 
without support at the age 15 months, although he showed delay in attaining language 
and failure to thrive (weight always around 3rd centile) from the first months of life. 
Preliminary genetic investigations (karyotype, MLPA 22q12.2, telomeres, fragile X) 
yielded no abnormalities. Moreover, gastroenterological and endocrinological 
investigations (FT4, TSH, IgA, EMA, Anti TG, AGA) carried out during hospitalization 
showed increased GOT (84.9 IU/L), central hypothyroidism (TSH levels 1.27 mU / ML, 
Ft3 2.4 pg/ml with NV of 2.4-4.2 and Ft4 7.6 pg/ml with NV of 8.5-16.5) and low levels 
of ACTH (18 pg/ml with NV of 0-46 pg/ml). During the follow up increased serum 
lactate was detected (4.71 mmol/l, NV 0.6-2.3 mmol/l). The child was treated with 
thyroid hormone and started therapy with hydrocortisone. Around age 3 years the boy 
started with a prolonged repetitive left hemiclonic SRSE and additional single episodes 
relapsed during the follow-up with a frequency of at least twice a month although he was 
taking antiepileptic polytherapy with phenobarbital, topiramate, and clonazepam. At age 
7 years serial brain MRIs performed three times in a timeframe of 3 months, showed only 
a slight global cerebral atrophy, and a cortical DTW restriction hyperintensity was 
observed only once in the right precentral gyrus (Figure 1 G-J). MR spectroscopy did not 
detect any lactate peek. Polymyographic video/EEG recordings during one episode of 
SRSE with subsequent left focal myoclonic seizures, showed, only as a counterpart of the 
seizures, a pattern of RHADs (Rhythmic High Amplitude Delta superimposed by fast 
activity) over the contralateral central regions. Focal RHADs were also present during 
sedation. Later on, during the SRSE, which was treated with topiramate, propofol and 
ketamine, RHADs were no longer recorded, and were replaced by persistent focal slow 
activity. SRSE lasted 17 days together with epilepsia partialis that was noticed over the 
left side of the body. 
Patient 3. The girl is the second child from unrelated parents; an eldest sister aged 12 
years was healthy. She was born by a planned TC delivery, at term, and weight was 
2.950 kg at 40 weeks of gestation. The child had a normal development from the 
newborn period to the age of 5 years, although a mild hearing loss was suspected. 
Around the age of 5 years she was admitted to the intensive care for the abrupt 
manifestation of a myoclonic status epiplepticus during an intercurrent febrile episode. 
The patient needed a prolonged hospital admission because she manifested repeated 
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severe myoclonic or right prolonged hemiclonic SRSE that was associated with a 
psychomotor deterioration. During the follow up the child presented with very frequent 
and long duration seizures of generalized or hemiclonic SRSE and a persistent interictal 
myoclonus at upper and lower limbs. One previous brain MRI performed at age 3 years 
was considered normal, while the last brain MRI performed at age 7 years (Figure 2A-D) 
showed global cortical atrophy that was prominent in both the right hemisphere and the 
homolateral cerebral peduncle. There was also abnormal T2 high intensity signal (long 
TR images) of the deep white substance at the semi-oval white matter and in the 
paratrigonal site bilaterally with involvement of the subcortical spaces in the temporo-
insular areas bilaterally (data not shown). The DWI study did not show any signs of 
recent cerebral and cerebellar parenchymal abnormalities. The ventricular system was 
moderately enlarged. Polygraphic video/EEG recordings performed during the chronic 
phase of the disease showed poorly organized cerebral activity, both in wakefulness and 
sleep, with theta activity superimposed by fast rhythms. Polymyographic recording 
confirmed right side high frequency myoclonus, predominantly at the right hand and 
right face, rhythmic in nature, persistent during sleep, without a clear-cut correlation with 
the EEG transients. 
Patient 4 is the only child from unrelated parents. A half-brother from previously 
mother’s marriage presented with severe psychomotor delay, refractory epilepsy and 
myoclonic status epilepticus at 2 years of age; he died for unknown reason at 3 years. 
This boy was born at term after an uncomplicated pregnancy and delivery. Psychomotor 
delay was reported since the first months of life: he achieved sitting position at 12 
months, autonomous gait and first words at 3 years of age. First neurological evaluation 
performed at 4 years showed psychomotor delay and pyramidal signs at lower limbs; 
instrumental exams including brain MRI and EEG were reportedly normal. At 5 years 
and 5 months of age, few days after a viral illness, he presented partial motor status 
epilepticus. In the following months, refractory epilepsy and psychomotor regression 
were reported. He manifested motor partial, tonic, myoclonic seizures and spasms, and 
experienced two episodes of myoclonic status epilepticus resembling SRSE, refractory to 
midazolam, thiopentone, vitamin B6 and propofol. EEGs were not available; brain MRI 
performed one month after first status epilepticus disclosed T2 hyperintensities in 
thalami and in right hemisphere temporo-parieto-occipital cortex that appeared reduced 
40 days later when a serial brain MRI was performed (Suppl. Figure S1 A-E). He was 
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admitted to our hospital at 5 years and 9 months manifesting spastic tetraparesis, no 
postural control, hyperkinesis but poor voluntary movements and severe cognitive 
impairment. Seizures frequency was daily. Polymyographic video/EEG disclosed 
epilepsia partialis continua at the right arm intermingled with asymmetric tonic seizures 
mainly involving left side arm and related with generalized low voltage fast rhythms with 
parieto-occipital prevalence, EEG background activity and sleep pattern were not 
organized. Brain MRI showed global cerebral atrophy (Suppl. Figure S1 F-J). Visual and 
sensory evoked potential showed central conduction abnormalities, motor and sensory 
nerve conduction velocities disclosed sensitive and motor axonal neuropathy. Fundus 
oculi and brainstem auditory evoked were normal. Blood routine exams, pyruvate, amino 
acids plasmatic levels, very long chain fatty acid (VLCFA), phytanic acid and urinary 
organic acids were normal. Mild elevated lactate level in serum was detected (2.3 mmol/l 
nv 0.8-2.1). Respiratory chain complexes activity was normal in muscle. Patient died for 
respiratory failure at 6 years of age. 
Patient 5 is the only child from unrelated parents. Family history was unremarkable. She 
was born at term after an uneventful pregnancy. At birth weight was 3.050 kg, Apgar 9-
9. After birth, she presented respiratory distress that required intensive care and oxygen 
supplementation for 20 days. During the first months, psychomotor development was 
reportedly normal (head control at 2 months of age). Between 4-6 months of age 
development delay and failure to thrive became evident; from 7-8 months to 1 years of 
age she suffered from self-inflicted finger and mouth ulcers and pain insensitivity was 
reported (i.e. receiving vaccine injections). In the second year of life she presented 
prolonged clonic seizures at left face. At 3 years of age she was first evaluated in our 
institute: she presented with short stature (weight and length <3rd percentile), 
microcephaly (<3rd percentile), dysphagia, tetraparesis with extrapyramidal signs, 
dystonic postures involving both upper and lower limbs, dyskinesias and athetoid 
movements, absence of postural control, absence of language. Epileptic seizures were not 
noticed from parents but polymyographic video/EEG recorded tonic seizures at upper 
limbs related with multifocal generalized epileptiform abnormalities and showed poorly 
organized cerebral activity, both in wakefulness and sleep. Treatment with 
leveretiracetam was started but EEG pattern remained unchanged. From the age of 4 
years dyskinesias and dystonia worsened. Serial bran MRI (7 months 2 ys and 1 month, 4 
ys and 4 months) showed thin corpus callosum together with signs of increased cortical 
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subarachnoid spaces suggesting cortical involvement, and progressive cerebellar atrophy 
(Suppl. Figure S2); no cortex involvement was noticed. Brainstem auditory evoked and 
visual evoked potential showed central conduction abnormalities, motor and sensory 
nerve conduction velocities disclosed sensitive and motor axonal neuropathy. Fundus 
oculi was normal. Blood routine exams, plasmatic uric acid, lactate and pyruvate in 
plasma and CFS, plasmatic amino acids levels, VLCFA were normal. Molecular analysis 
of PLA2G6, POLG1, NARP/MILS mutations were negative. Muscle biopsy was not 
performed. At last follow up, at 5 ys, clinical conditions were stable. 
Histological and biochemical analyses 
Histochemistry of the muscle sample of Pt.1, Pt.2, Pt.3 showed scattered fibers with a 
patchy reduction of cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
stain with aspects of polymorphic core like areas (Figure 3, left and central panels). 
Similarly areas of reduced immunoreactivity were observed using the TOMM20 
antibody confirming impairment of the mitochondrial network distribution (Figure 3, 
right panel). Muscle histochemistry in Pt.4 also showed multiple areas of patchy 
reduction of cytochrome c oxidase (Suppl. Figure S3 A), while Electron Microscopy 
(EM) showed enlarged mitochondria; sometimes two mitochondria were coupled and 
appeared to be in close relationship to each other (Suppl. Figure S3 B-C). Occasionally, 
the sarcomeric organization appeared to be normal, though the Z line was often absent 
(Suppl. Figure S3 D). In addition, in some areas mitochondria were quite absent (Suppl 
S3 Fig E-F), whereas in others they were present in large collections (Suppl S3 Fig G-H). 
Histochemical serial sections of the muscle biopsy in Pt. 3 showed that fibers devoid of 
mitochondria were type 1 fibers (Supp. Figure S4). Furthermore, confocal microscopy of 
the muscle biopsy (Supp. Figure S5, Supp. Figure S6) showed an altered and irregular 
array of Z-bands, while patchy areas devoid of mitochondria were clearly observed with 
TOM20 staining. In spite of the irregular aspect of the Z bands in confocal microscopy, 
no major alterations such as streaming of the Z bands were observed at the EM level 
(Supp. Figure S3).  
Histochemistry of the muscle sample of a patient harboring compound heterozygous 
mutations in OPA1 (Nasca et al., 2017) was studied and compared with those of DNM1L 
patients and showed no patchy staining abnormalities (Figure 3 lowest panel). In 
addition, by Long Range PCR we also searched comparatively for multiple deletions in 
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muscle samples and found multiple deletions only in the OPA1 mutated patient and no in 
the DNM1L patients (data not shown). 
Muscle biopsy was not performed in Pt.5. 
RCCs biochemical analysis in muscle homogenate was normal in all patients (data not 
shown). Accordingly, the activity of Complex V (in the direction of synthesis of ATP) 
measured in Pt.1 fibroblast mitochondria, as well the oxygen consumption in Pt.4 and 
Pt.5 fibroblasts were normal (data not shown). 
Mutational analysis 
Bioinformatics analysis carried out on the TruSight One panel, performed in Pt.1, Pt.2 
and Pt.3, led to the identification of a single gene entry, DNM1L (NM_012062, 
NP_036192). In Pt.1 we identified the heterozygous, previously unreported variant 
c.668G>T (p.Gly223Val) (Figure 4A); in Pt.2 we identified the heterozygous variant 
c.1207C>T (p.Arg403Cys), already reported (Fahrner et al., 2016) (Figure 4B); in Pt.3 
we identified the heterozygous unreported variant c.1109T>G (p.Phe370Cys) (Figure 
4C). Segregation for the three mutations in the corresponding families was negative, and 
then they can be considered as de novo mutations. Similar filtering analysis was applied 
to the panel, containing ~230 genes associated with mitochondrial disease, used for Pt.4 
and Pt.5. In Pt.4 we identified 2 heterozygous DNM1L variants: c.1085G>A 
(p.Gly362Asp) and c.1535T>C (p.Ile512Thr) (Figure 4D-D’). The first nucleotide 
change corresponded to rs148686457, with a frequency 0.008% in the ExAC database, 
whereas the second was not reported in any public database. Given that DNM1L 
mutations may present as recessive or dominant traits, we evaluated the segregation in 
the healthy parents of Pt.4 by Sanger sequencing: we found that the c.1535T>C 
(p.Ile512Thr) was inherited from the mother (Figure 4D’) while the c.1085G>A 
(p.Gly362Asp) was not present in any of the two parents and may represent a de novo 
event (Figure 4D). Indeed, the same change has been recently reported as a de novo 
mutation (Vanstone et al., 2016). An in-depth evaluation of the familial history revealed 
that the mother had a son with epileptic encephalopathy from another man. This child 
died at 3 years of age: no material was available for genetic studies. By subcloning PCR 
products obtained from Pt.4’s cDNA, we were able to assess that the two DNM1L 
variants were on the same allele (i.e., the maternal allele, harboring the c.1535T>C 
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variant identified in the mother). Moreover, a further analysis of DNM1L genomic region 
using a next-generation sequencing (NGS) approach revealed that the c.1085G>A was 
present in the mother’s blood DNA, although at very low level (~5%). These findings 
suggested a maternal germline mosaicism for the dominant mutation c.1085G>A 
(p.Gly362Asp), that may even explain the affected status of the Pt.4’s half-brother 
(Suppl. Figure S7). In Pt.5 we identified a heterozygous variant c.1084G>A 
(p.Gly362Ser); the variant was not detected in the parents’ DNA by Sanger or NGS 
analyses (Figure 4E). The variant was absent in public SNP databases; nevertheless, it 
was reported as a de novo mutation in a patient with refractory epilepsy (Sheffer et al., 
2015). 
All new mutations herein reported were pathogenetic while tested in silico (Suppl. Table 
S2), and were not reported in public (dbSNP142, ExAC, 1000 Genomes, HGMD, 
gnomAD) and in-house databases. 
Western blotting analysis 
To evaluate the impact of the mutations on DRP1 stability, we performed WB analysis 
on fibroblasts. We observed a significantly increased (in Pt.3) or normal (in Pt.1, Pt.2, 
Pt.4 and Pt.5) level of the protein when normalized to GAPDH (Figure 5A-B), in contrast 
with the strong reduction present in DNM1L-recessive cases (Nasca et al., 2016). The 
expression level of OPA1 and of different subunits of the RCCs showed no differences 
compared to controls (data not shown). 
Immunostaining and imaging in cultured fibroblasts 
Because of the pivotal role of DRP1 on dynamics of mitochondria and peroxisomes, we 
performed morphological studies on patients’ fibroblasts. We used the antibody 
TOMM20 in fixed cells (for Pt.1, Pt.2 and Pt.3) or Mitotracker red in living cells (for 
Pt.4 and Pt.5), both specific for mitochondrial staining. In normal glucose medium we 
observed an increased filamentous network in mutant fibroblasts of all patients (Suppl. 
Figure S8, left panels), although Pt.1 displayed a mixed population in which hyperfused 
mitochondria are associated with swollen and rod-shaped mitochondria and Pt.5 showed 
dot-shaped mitochondria (Figure 6, left panel). In galactose-supplemented medium, a 
condition that forces cells to use the oxidative phosphorylation for ATP production and 
usually causes elongation of mitochondrial network in control cells, the mitochondrial 
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network of DNM1L-mutant fibroblasts showed a lower tendency to fuse associated with a 
more disorganized network and an altered mitochondria morphology, with swollen, dots, 
rings, and “chain-like” structures (Figure 6, right panels; Suppl. Figure S8 right panels). 
For the immunovisualization of peroxisomes, we used an antibody against a peroxisomal 
protein, PMP70. In contrast with the highly diffused punctuated staining present in 
control cells, in Pt.4 and Pt.5 cytoplasm (Figure 7) we observed organelles longer, larger, 
and less uniformly distributed into cytoplasm; although in minor extent, peroxisomal 
alterations were present also in Pt.1, Pt.2 and Pt.3 (Suppl. Figure S9). Accordingly, the 
morphometric analysis showed decreased form factors for circularity in the patient’s cells 
compared to controls, with a significant reduction for Pt.4 and Pt.5 (Figure 7; Supp. 
Figure S9). 
Functional studies in yeast  
The deleterious effect of the p.Arg403Cys substitution was already experimentally 
demonstrated (Fahrner et al. 2016). To assess the pathogenic role of the other identified 
DNM1L variants as well as to compare the effects of different substitutions on the same 
amino acid (p.Gly362), we performed complementation studies in a S. cerevisiae strain 
lacking DNM1, hereafter referred to as Δdnm1. DNM1 is the yeast orthologue of human 
DNM1L; the amino acid residues corresponding to p.Gly223Val, p.Gly362Asp, 
p.Gly362Ser and p.Ile512Thr variants are conserved between the two species, being in 
yeast p.Gly252, p.Gly397, p.Ile543, whereas human p.Phe370 is not conserved, being 
p.Tyr405 in yeast. The dnm1Δ strain was transformed either with the wt DNM1, the 
dnm1G252V, dnm1G397D, dnm1G397Sor dnm1I543T mutant alleles, under the endogenous 
DNM1 promoter, as well as with the empty plasmid. To test the possible effects on 
mitochondrial function, we first evaluated the oxidative growth by spot assay analysis on 
medium supplemented with either glucose or ethanol or glycerol. The oxidative growth 
of the dnm1G397D and the dnm1G397S mutant strains was partially affected compared to the 
DNM1 wild type strain, especially on ethanol, whereas the growth of the dnm1G252V was 
similar to the strain dnm1Δ; on the contrary the growth of the dnmII543T mutant was 
unaffected (Figure 8A). To further investigate the OXPHOS defect, the oxygen 
consumption was measured and according to the growth phenotype, the oxygen 
consumption rate of the dnm1G397D and of the dnm1G397S mutants was respectively 30% 
and 20% lower than that of the wild type strain, whereas the oxygen consumption rate of 
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dnm1G252V and of the dnm1 null strain was decreased by 60%; also the dnmII543T mutant 
showed a slight though significant reduction of respiratory activity (Figure 8B). In yeast, 
mutations in several nuclear genes encoding for proteins involved in mitochondrial 
dynamics, such as MGM1 (the homologous gene of human OPA1), (Sesaki et al., 2003; 
Nolli et al., 2015), FZO1 (hMFN1), (Rapaport et al., 1998) and DNM1 itself (Bernhardt 
et al., 2015), affect mtDNA stability. Although the patients reported in this study did not 
show any mtDNA defects, we measured the frequency of petite, i.e. clones which are 
unable to grow on an oxidative carbon source due to large deletions or lack of mtDNA, 
in order to further highlight the defect of mutant Dnm1 proteins. Deletion of DNM1 as 
well as the expression of dnm1G252V resulted in a significant increase of petite frequency 
(∼50%) compared to the wild-type strain, whereas expression of dnm1G397D or dnm1G397S 
partially decreased mtDNA stability (∼40% and ∼25%, respectively), which is, however, 
lower than the DNM1 wild-type strain or the dnmII543T (∼8% and ∼15%, respectively) 
(Figure 8C). 
Altogether these results validated the pathogenicity of the mutations Gly252Val, 
Gly397Asp and Gly397Ser, showing also that substitution of Gly397 with aspartate is 
more deleterious than substitution with serine. The amino acid change Ile543Thr slightly 
affects the activity of the protein as well, being the respiratory activity and the petite 
frequency slightly altered compared to DNM1 wild type. Since the variant Ile512Thr was 
present in the patient in cis with the Gly362Asp, we also constructed a yeast mutant 
allele carrying both the corresponding variants. Interestingly, the dnm1G397D-I543T strain 
showed a more severe phenotype than the strain carrying the sole mutation Gly397Asp; 
in fact, the oxidative growth, the respiratory activity and the mtDNA mutability become 
similar to that of the null mutant suggesting that Ile543Thr is a phenotypic modifier 
(Figure 8A-C). 
Finally, we tested whether the mutations have a dominant or recessive effect by 
measuring the oxygen consumption rate of the diploid hemizygous DNM1/dnm1∆ strain 
transformed with the plasmid having mutant alleles or with the empty vector. The 
respiratory activity of the heteroallelic strains DNM1/dnm1G397D, DNM1/dnm1G397S and 
DNM1/dnm1G397D-I543T, but not that of DNM1/dnm1G252V and DNM1/dnm1I543T, was lower 
compared to the hemizygous strain DNM1/dnm1∆. This indicates that Gly397Asp and 
Gly397Ser have a partial dominant-negative effect whereas Ile543Thr and, quite 
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unexpectedly, Gly252Val act as recessive mutations (Figure 8D), at best concerning the 
effect on oxygen consumption. To better deepen this point, we investigated in the 
heteroallelic strain DNM1/dnm1G252V another phenotype, i.e the petite frequency, based 
on the observation that the mutation Lys41Ala, generally recognized as dominant (Frank 
et al., 2001), increased the petite frequency in an heteroallelic diploid mutant strain 
(Nasca et al., 2016). The significant increase (3.3-fold±0.6, p<0.001) of the petite 
frequency observed, compared to the hemizygous strain, suggests that also the 
Gly252Val mutation behaves as partially dominant, at least for this specific phenotype. 
Structural analysis 
All the identified missense mutations affect sites, which are totally or highly conserved 
sites among species (Figure 9A) and imply replacements with residues presenting 
physicochemical properties that differ significantly from those of the wild type amino 
acids. The p.Gly223Val mutation causes the substitution of the tiny and flexible glycine 
with a hydrophobic valine, which is expected to induce structural changes in the GTPase 
domain near residues 215-221 important for the binding of GTP (Figure 9B). The 
p.Gly362Asp and p.Gly362Ser mutations replace the tiny glycine with the anionic 
aspartic acid or with the hydrophilic serine, respectively, modifying the N-terminus of an 
α-helix also exploited in dynamin tetramerization (Figure 9C), as inferred by homology 
of dynamin-1-like with dynamin 3, another member of the dynamin family. The 
p.Phe370Cys mutation affects the large and hydrophobic phenylalanine that is important 
for the stability of monomers and for the tetramer formation (Figure 9D). In fact, Phe370 
is involved in several intramolecular hydrophobic interactions, which are disrupted by 
the replacement with the small cysteine and the latter might also become engaged in 
disulfide bond formation with other cysteines located nearby (Suppl. Figure S10). The 
p.Arg403Cys mutation implies the change of the cationic arginine into the tiny and 
neutral cysteine at sites that contribute to the core of tetrameric dynamin assembly 
(Figure 9E), as previously reported (Fahrner et al., 2016). 
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DISCUSSION 
Here we described five patients with epileptic encephalopathy and de novo dominant 
missense mutations in DNM1L. We identified two novel variants in Pt.1 and Pt.3, 
whereas in Pt.2 and Pt.5 we found two variants that were reported so far (Fahrner et al., 
2016; Sheffer et al., 2015). Pt.4 showed two variants on the same allele; the first was 
inherited from the mother and the second, recently described as a de novo mutation 
(Vanstone et al., 2016), was present in the mother’s blood DNA at low level (~5%), 
suggesting a maternal mosaicism. We observed a quite strict genotype-phenotype 
correlation, with overlapping clinical presentations between Pt. 2, Pt. 4, Pt. 5 and the 
previously described patients harboring the same mutation (reported by Fahrner et al., 
2016, Vanstone et al., 2016 and Sheffer et al., 2015 respectively). 
Following the first description of Waterham et al. (2007), there have been increasing 
reports in the last 2 years on patients, frequently sporadic, with de novo dominant-
negative DNM1L mutations who are affected by early onset encephalopathy with 
microcephaly and drug resistant seizures, progressive brain atrophy or abnormal brain 
development, optic atrophy, and occasionally persistent lactic acidemia. The degree of 
severity was broad, ranging from neonatal death to prolonged survival (Fahrner et al., 
2016; Zaha et al., 2016; Sheffer et al., 2016; Vanstone et al., 2016; Chao et al., 2016). A 
similar spectrum of clinical presentations has been also reported for DNM1L recessive 
mutations (Yoon et al., 2016; Nasca et al., 2016). More recently, dominant mutations in 
DNM1L have been also related to isolated optic atrophy in three large families (Gerber et 
al., 2017). 
The patients described here presented clinical manifestations quite similar to previously 
reported DNM1L cases manifesting early onset encephalopathy and characterized by 
development delay, together with episodes of SRSE, progressive cerebral atrophy, and 
transitory abnormal T2 hyperintensities and DTI restriction areas at MRI. In addition, 
elevated lactate level in serum was detected in Pt.2 and Pt.4, whereas lactate was normal 
in other patients. There are no clues about a peroxisomal dysfunction: when available 
(Pts 4 and 5), plasma phytanic and pristanic acids concentrations, typically increased in 
patients with peroxisomal disorders [ten Brink et al.,  1992], were normal. Excluding the 
16 patients with mild non-syndromic optic atrophy, six patients of the twelve reported in 
literature showing similar clinical manifestations died in early-childhood (Waterham et 
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al., 2007; Chao et al., 2016; Yoon et al., 2016; Zaha et al., 2016) and in four cases death 
occurred in the first year of age (Waterham et al., 2007; Chao et al., 2016; Yoon et al., 
2016). It is not clear why some mutations give rise to premature death. The cause of the 
early-childhood death cannot be attributed to the mode of transmission, since early death 
occurred both in patients with a dominant de novo mutation and in patients with recessive 
mutations (Waterham et al., 2007; Chao et al., 2016; Yoon et al., 2016; Zaha et al., 
2016), neither to the residual amount of DRP1, given that fibroblasts from a patient with 
long survival showed a strong reduction of the total amount of the protein (Nasca et al., 
2016). In the cohort of our patients only the Pt.4 died at six years of age, differently from 
the one already described with the same p.Gly362Asp mutation who showed prolonged 
survival (Vanstone et al., 2016). However, Pt.4 carried also a second, maternally 
inherited heterozygous DNM1L variant (p.Ile512Thr), which may explain the different 
degree of severity in these two cases; indeed, the yeast studies suggested that the 
p.Ile512Thr change can be a modifier, able to worsen the phenotype associated with the 
p.Gly362Asp mutation. 
Clinical signs of a severe epileptic encephalopathy with frequent episodes of SRSE and 
EEG abnormalities do not seem to be peculiar signs of this condition. Noteworthy, MRI 
abnormalities, and particularly the detection of transitory abnormal T2 hyperintensities 
and DTI restriction areas in the basal ganglia or the cortical areas are quite characteristic 
for DNM1L encephalopathy, although may rarely occur in other conditions such as 
MELAS or may represent a unspecific sign due to status epilepticus. 
Probably the most peculiar finding in the cohort of our patients is the muscle 
histology/histochemistry showing core like areas using oxidative enzyme staining for 
COX and SDH, which suggest an abnormal distribution of mitochondria in the muscle 
tissue. We found this pattern in all the examined muscle biopsies. Notably, reduced 
mitochondrial numbers and size and a paucity of mitochondria between sarcomeres in 
muscle have been noticed in transgenic Drosophila models expressing DNM1L variants 
identified in patients (Chao et al., 2016). Areas devoted of mitochondria have not been 
found in muscle biopsies of OPA1 mutated patients that can sometimes show ragged red-
COX negative fibers correlated with mitochondrial DNA instability (Amati-Bonneau et 
al., 2008). In the investigated patient with recessive OPA1 defect, although COX 
negative fibers were not detected, we confirmed multiple deletions. Contrariwise, in 
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muscle samples of DNM1L patients, the impairment of the mitochondrial network 
distribution was not associated with mitochondrial DNA instability. 
The primary sequence of DRP1 consists of four conserved regions: the GTPase domain, 
the middle, the variable, and the GTPase effector domain (GED). Revising all the cases 
published, we noted that mutations that fall into the GTPase domain are typically 
associated with a recessive trait (except for the cases not associated with early 
encephalopathy, reported by Gerber et al., 2017), while mutations that fall into the 
middle domain are expressed as dominant-negative. Here, we report on four mutations 
falling in the middle domain, which we suggest having a dominant negative effect on the 
oligomers stability. In fact, we likely exclude a DRP1 haploinsufficiency, as we observed 
normal or significant increase of protein level by western blotting analysis. Moreover, we 
excluded a gain of function effect on the physiological activity of DRP1 because we did 
not observe increase in mitochondrial fission; on the contrary patient’ fibroblasts showed 
hyperfused mitochondria. In only one of our patients (Pt. 1) we identified a mutation 
(p.Gly223Val) which falls into the GTPase domain, even if the nucleotide change is 
located at the boundary between the GTPase and the central domain. The yeast model 
indicated that it acts with a dominant-negative effect but probably through a mechanism 
different from the other mutations located in the middle domain. It is possible that the 
same mechanism may explain also the cases with isolated optic atrophy, harboring 
dominant mutations in the GTPase domain (Gerber et al., 2017); nevertheless, a gain of 
function effect has been postulated as well (Wangler et al., 2018). 
In the cytosol, DRP1 exists as a mixture of dimers and tetramers (Macdonald et al., 2014) 
and, when recruited to mitochondria via receptors anchored to the mitochondrial outer 
membrane (Losón et al., 2013), hydrolysis of GTP triggers conformational changes in 
DRP1 oligomers that generate the mechanical force to promote mitochondrial membrane 
scission (Francy et al., 2015). The middle and GED domains promote DRP1 self-
assembly, required for mitochondrial fission (Chang et al., 2010), while the variable 
domain seems to act as a negative regulator of DRP1 self-assembly (Francy et al., 2015). 
Structural analysis revealed hypothetical mechanisms of protein impairment and 
malfunctioning for all the missense mutations presented in this study. Specifically, the 
p.Gly223Val substitution seems to hamper the binding of GTP, hence the GTPase 
activity, the p.Gly362Asp mutation impairs the tetramer formation, as previously 
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described by the two-hybrid experiment of Farhner et al., 2016. Finally, also the 
p.Phe370Cys could influence the protein oligomerization. In the patient fibroblasts with 
this mutation we observed a significant increase of DRP1 level probably due to its altered 
degradation, in fact this amino acid change might cause disulfide-mediated abnormal 
multimerization. As matter of fact, in the protein structure the p.Phe370Cys mutation is 
located close to the mouse p.Cys452Phe substitution (p.Cys446Phe in the human 
protein), which has been demonstrated to cause an increase in higher-ordered assembly 
with supranormal GTPase function and a failure of oligomer disassembly (Cahill et al., 
2016). 
At the cellular level we found the presence of hyperfused, swollen and rod-shaped 
mitochondria in fibroblasts from all our patients, as reported for others DNM1L 
mutations (Waterham et al., 2007, Fahrner et al., 2016; Zaha et al., 2016; Sheffer et al., 
2016; Vanstone et al., 2016; Nasca et al., 2016; Gerber et al., 2017; Ladds et al., 2018; 
Ryan et al., 2018). The morphological anomalies were not associated with overt 
OXPHOS dysfunctions, in fact we did not observe reduction of OXPHOS subunits levels 
and cellular respiration was unaffected. Likewise, the activities of the MRC complexes in 
muscle were normal in the four patients of our cohort for whom muscle biopsy was 
obtained. The same findings have been reported in most of the DNM1L-mutant cases; in 
only few patients slightly decreased activity of complex IV, altered ATP production or 
impaired oxygen consumption were observed in fibroblasts (Sheffer et al., 2016; Nasca et 
al., 2016), or in muscle (Ladds et al., 2018). Surprisingly, histochemistry of Pt.1, Pt.2, 
Pt.3 and Pt.4 showed scattered fibers with a partial reduction of COX and SDH stainings, 
and with aspects of polymorphic core like areas. Moreover, we also identified areas with 
reduced immunoreactivity to mitochondrial signal, suggesting an abnormal distribution 
of organelles. Accordingly, the EM examination showed a few fields, mainly located at 
the center of the fibers, devoid of mitochondria. In these areas the sarcomeric 
organization was quite normal, though the Z lines were often absent (Supp. Figure S3) as 
reported in selenoprotein-related diseases (Cagliani et al., 2011), or somewhat irregular 
(Supp. Figure S5, Supp. Figure S6). Interestingly, at EM the areas devoid of 
mitochondria did not show any major misalignment such as streaming of the Z-bands, 
that is well known to occur in the cores which are typically devoid of oxidative stains in 
RYR1 related myopathies (Monnier et al; 2000). This is a new finding and can be 
considered as a key aspect suggesting mutations in DNM1L. In fact, no peculiar 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
histochemical alterations have been reported so far in the muscle biopsies of DNM1L 
patients. The histological features of muscle biopsies associated with the de novo 
dominant mutation p.Arg403Cys, very recently reported (Ladds et al., 2018), are often 
found in other mitochondrial diseases and cannot be considered specific for DRP1 
impairment. 
In addition to mitochondrial fission, DRP1 is also implicated in the division of 
peroxisomes (Schrader et al., 2016); to this purpose we investigated peroxisomal 
morphology and in fibroblasts from Pt. 4 and Pt. 5 we observed organelles significantly 
longer, larger, and less uniformly distributed into cytoplasm, in contrast with the highly 
diffused punctuated staining present in control cells; the same condition has been 
described for other patients with mutations in DNM1L (Waterham et al., 2007; Nasca et 
al., 2016; Zaha et al., 2016) and in transgenic Drosophila model expressing a mutant 
form of DNM1L (Chao et al., 2016). 
It is not clear why defects of mitochondrial and peroxisomal fission affect predominantly 
the nervous system. It was demonstrated that DRP1 is required for embryonic and brain 
development in mice (Ishihara et al., 2009; Wakabayashi et al., 2009). Particularly, 
DRP1 knockout (KO) caused alteration of mitochondrial morphology and proliferation of 
embryonic Purkinje cells, suggesting that their development depends highly on 
mitochondrial division (Wakabayashi et al., 2009). Subsequently, it has been 
demonstrated that loss of DRP1 led to accumulation of oxidative damage, decreased 
respiratory function, and neurodegeneration also in post-mitotic Purkinje cells, while 
DRP1 KO Mouse Embryonic Fibroblasts (MEFs) maintain normal respiration and ATP 
levels (Kageyama et al., 2012). Given that post-mitotic neurons contain high ROS levels 
and do not proliferate, the mitochondrial quality control mechanism is essential, while in 
MEFs, which actively proliferate, mitochondria are produced continuously during cell 
proliferation and therefore the effect of any oxidative damage may be diluted by the 
newly formed mitochondria. Moreover, a previous study has shown that the delivery of 
mitochondria into dendritic protrusions in response to synaptic stimulation is strictly 
dependent on an efficient mitochondrial transport, that requires DRP1-dependent division 
(Li et al., 2004); altered mitochondrial distribution likely affects the function and 
formation of synapses as well as the survival of neurons (Sheng & Cai, 2012; Sheng, 
2017). Therefore, the retained DRP1 activity is likely sufficient for organs with limited 
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mitochondrial remodeling, while impaired DRP1 activity could strongly affect the 
nervous system, thus explaining the involvement of DRP1 in many neurodegenerative 
disorders. 
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Figures 
Figure 1 MRI pattern of Pt.1 (A-F) obtained at age 6 years and Pt.2 (G-J) obtained at age 
7 years. A: T2 weighted axial image; B: FLAIR weighted axial image; C-D: serial DTI 
images obtained serially in two different days of the same month. In Pt1 the MRI shows 
signs of global cerebral and cerebellar atrophy, with moderate enlargement of the 
ventricles. Two serial brain axial DTI weighted MRIs were performed in the same month 
with a distance of 20 days; the first MRI showed a cortical DTW restriction 
hyperintensity in the right precentral gyrus, and abnormal DTI restriction hyperintensities 
corresponding to the pallidum and thalamus of the right hemisphere (C). These 
abnormalities vanished spontaneously 20 days later when a serial brain MRI was 
performed (D). In Pt.2 the T1 weighted sagittal image (G) and axial T2 weighted (I) and 
corresponding axial FLAIR weighted images were consistent with a slight global 
cerebral atrophy, while a cortical DTW restriction hyperintensity was observed only once 
in the right precentral gyrus (G-J) out of 3 MRI scans performed within 3 months of 
time. 
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Figure 2 MRI pattern of Pt3. Brain MRI performed at age 7 years. A: T2 weighted axial 
image; B: the corresponding FLAIR weighted axial image; C: sagittal T1 weighted; D: 
coronal T2 weighted image, showing global severe cortical atrophy that was prominent 
in both the right hemisphere and the homolateral cerebral peduncle (A-B). 
 
Figure 3 Panel showing the histochemistry of quadriceps muscle samples of Pt.1, Pt.2, 
Pt.3 and control. The muscle histochemistry of serial sections of three patients with 
heterozygous dominant mutations in DNM1L and stained with cytochrome c oxidase 
(COX) and succinate dehydrogenase (SDH) showed scattered fibers with a patchy 
reduction of both COX and corresponding SDH staining, with aspects of polymorphic 
core like areas (left and central panel). Similarly areas of reduced immunoreactivity were 
observed using the TOMM20 antibody confirming impairment of the mitochondrial 
network distribution (right panel). These abnormalities were not detected in the muscle 
biopsy of a patient with biallelic mutations in OPA1 (last bottom row) already described 
(Nasca et al., 2017). The plasma membrane is stained in red fluorescence with an 
antibody against dystrophin. 
 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
Figure 4 Electropherograms. The variants identified by NGS in DNM1L (A-E) have 
been confirmed by Sanger sequencing in all patients and their parents. In D’ the second 
variant identified in Pt.4 (c.1535T>C), inherited from the mother. 
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Figure 5 Western blotting analysis. Immunoblot analysis of total lysates from controls 
(Ct) and patients (Pt) fibroblasts using DRP1, VDAC, and GAPDH antibodies. The latter 
was used as loading control. The steady state level of DRP1 protein is significantly 
increased in Pt.3 fibroblasts. Values in the graph are given as the mean ± SD (n = 4 to 5); 
*, p<0.05. 
 
Figure 6 Characterization of the mitochondrial network: analysis by fluorescence 
microscopy. A-B: Representative images of mitochondrial morphology in fibroblasts 
from Pt.1, Pt.5 and Ct, grown either in glucose or galactose medium. In glucose medium 
(left panel) patients’ fibroblasts are characterized by a mixed population with hyperfused 
swollen and rod-shaped mitochondria; in galactose medium (right panel) the 
mitochondrial network of patients’ fibroblasts showed a lower tendency to fuse 
associated with a more disorganized network and an altered mitochondria morphology, 
with swollen, dots, rings, and “chain-like” structures. (Scale bar: 25 μm). 
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Figure 7 Characterization of the peroxisomal network: analysis by fluorescence 
microscopy. Immunofluorescence staining with the anti-PMP70 antibody of fibroblasts 
from Ct, Pt.4 and Pt.5. Patients’ fibroblasts displayed organelles longer, larger, and less 
uniformly distributed into cytoplasm compared to control (Scale bar: 25 μm). A form 
factor (“circularity”) value of 1.0 indicates a perfect circle; values approaching to 0.0 
indicate increasingly elongated shapes. 
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Figure 8 Functional studies in yeast. A: Phenotypic analysis of haploid strains through 
spot assay. Serial cell dilutions (5x104, 5x103, 5x102 and 5x101 cells/spot) of dnm1∆ 
haploid strain transformed with DNM1 wild type or mutant alleles were spotted on SC 
medium supplemented with either 2% glucose or 2% glycerol. Pictures were taken after a 
3-days incubation at 37°C. B: Petite frequency of dnm1∆ haploid strain transformed with 
DNM1 wild type or mutant alleles. Values are means of six to eight independent clones ± 
SD. **(p<0.01) and ***(p<0.001) in a ANOVA test followed by a Bonferroni’s test. C: 
Respiratory activity of dnm1∆ haploid strain transformed with DNM1 wild type or 
mutant alleles. Values are means ± SD of experiments on five clones and have been 
normalized to the respiratory activity of the DNM1 wt strain. *(p<0.05) and 
***(p<0.001) using ANOVA with post-hoc Bonferroni’s test. D: Respiratory activity of 
DNM1/dnm1∆ diploid strain transformed with DNM1 wild type or mutant alleles. Values 
are means ± SD of experiments on five clones and have been normalized to the 
respiratory activity of the DNM1 wt strain. *(p<0.05) and ***(p<0.001) using ANOVA 
with post-hoc Bonferroni’s test. 
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Figure 9 Conservation and structural mapping of residues affected by the missense 
mutations G223V, G362D, F370C, and R403C. A: multiple sequence alignment among 
species (invariant columns are grayed). B: mapping of G223 on the crystal structure of a 
dimeric human dynamin-1-like protein (PDB 3W6O; residues 215-221, colored in 
magenta, are important for GTP binding; the cocrystallized nucleotide analogue is shown 
as sticks). Mapping of G362 (C), F370 (D), and R403 (E) on dynamin tetramer (PDB 
5A3F). The red dotted lines indicate the disordered regions in which R403 is hosted in 
two of the four dynamin monomers. The different dynamin chains are in distinct colors. 
Amino acid numbering is made according to the isoform 1 of dynamin-1-like protein 
(NP_036192.2). 
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